EU approves Novartis' IL-17 mono-anti-Cosentyx for treatment of non-radiation axial spinal arthritis
-
Last Update: 2020-05-29
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Novartis Pharmaceuticals announced that the European Commission has approved its IL-17 mono-anticosentyx (secukinumab) for the treatment of adults with active non-radiation axial spinal arthritis (nr-axSpA)The approval makes the drug the first all-human source IL-17A monoantigen approved for the indicationThe company also filed applications in the United States and Japan to approve Cosentyx for the treatment of nr-axSpA adultsEuropean approval was based on Phase III PREVENT study data, with 41.5 percent of patients treated with Cosentyx showing significant and clinically significant remission, compared with 29.2 percent in the placebo groupThe ASAS40 score for patients treated with Cosentyx showed that 40% of patients treated with Cosentyx achieved improvement satin at week 16 and were able to maintain it until 52 weeksSignificant improvements in secondary endpoints were also demonstrated, including pain, disease burden and health-related quality of lifeEric Hughes, head of global development at Novartis,, said the latest approval was 'a step in our plan to expand Cosentyx to 10 indications over the next 10 years.' The drugwas also licensed for the treatment of moderate to severe plaque psoriasis, psoriasis arthritis and severe syllade sylline, with sales of $930 million in the first quarter of 2020, up 18% year-on-year
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
